Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.

Hermes Florez, Qing Pan, Ronald T. Ackermann, David G. Marrero, Elizabeth Barrett-Connor, Linda Delahanty, Andrea Kriska, Christopher D. Saudek, Ronald B. Goldberg, Richard R. Rubin, Prevention Program Research Group Diabetes Prevention Program Research Group

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL). To assess changes in HRQoL after interventions aimed at diabetes risk reduction. A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean age 51 years, mean BMI 34 Kg/m(2); 68 % women, and 45 % members of minority groups. Intensive lifestyle (ILS) program with the goals of at least 7 % weight loss and 150 min of physical activity per week, metformin (MET) 850 mg twice daily, or placebo (PLB). HRQoL using the 36-Item Short-Form (SF-36) health survey to evaluate health utility index (SF-6D), physical component summaries (PCS) and mental component summaries (MCS). A minimally important difference (MID) was met when the mean of HRQoL scores between groups differed by at least 3 %. After a mean follow-up of 3.2 years, there were significant improvements in the SF-6D (+0.008, p=0.04) and PCS (+1.57, p<0.0001) scores in ILS but not in MET participants (+0.002 and +0.15, respectively, p=0.6) compared to the PLB group. ILS participants showed improvements in general health (+3.2, p<0.001), physical function (+3.6, p<0.001), bodily pain (+1.9, p=0.01), and vitality (+2.1, p=0.01) domain scores. Treatment effects remained significant after adjusting sequentially for baseline demographic factors, and for medical and psychological comorbidities. Increased physical activity and weight reduction mediated these ILS treatment effects. Participants who experienced weight gain had significant worsening on the same HRQoL specific domains when compared to those that had treatment-related (ILS or MET) weight loss. No benefits with ILS or MET were observed in the MCS score. Overweight/obese adults at high risk for diabetes show small improvement in most physical HRQoL and vitality scores through the weight loss and increased physical activity achieved with an ILS intervention.

Original languageEnglish (US)
Pages (from-to)1594-1601
Number of pages8
JournalJournal of General Internal Medicine
Volume27
Issue number12
StatePublished - 2012
Externally publishedYes

Fingerprint

Metformin
Life Style
Quality of Life
Weight Loss
Exercise
Placebos
Minority Groups
Health
Risk Reduction Behavior
Health Surveys
Weight Gain
Comorbidity
Fasting
Therapeutics
Randomized Controlled Trials
Demography
Psychology
Glucose
Pain

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Florez, H., Pan, Q., Ackermann, R. T., Marrero, D. G., Barrett-Connor, E., Delahanty, L., ... Diabetes Prevention Program Research Group, P. P. R. G. (2012). Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine, 27(12), 1594-1601.

Impact of lifestyle intervention and metformin on health-related quality of life : the diabetes prevention program randomized trial. / Florez, Hermes; Pan, Qing; Ackermann, Ronald T.; Marrero, David G.; Barrett-Connor, Elizabeth; Delahanty, Linda; Kriska, Andrea; Saudek, Christopher D.; Goldberg, Ronald B.; Rubin, Richard R.; Diabetes Prevention Program Research Group, Prevention Program Research Group.

In: Journal of General Internal Medicine, Vol. 27, No. 12, 2012, p. 1594-1601.

Research output: Contribution to journalArticle

Florez, H, Pan, Q, Ackermann, RT, Marrero, DG, Barrett-Connor, E, Delahanty, L, Kriska, A, Saudek, CD, Goldberg, RB, Rubin, RR & Diabetes Prevention Program Research Group, PPRG 2012, 'Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.', Journal of General Internal Medicine, vol. 27, no. 12, pp. 1594-1601.
Florez, Hermes ; Pan, Qing ; Ackermann, Ronald T. ; Marrero, David G. ; Barrett-Connor, Elizabeth ; Delahanty, Linda ; Kriska, Andrea ; Saudek, Christopher D. ; Goldberg, Ronald B. ; Rubin, Richard R. ; Diabetes Prevention Program Research Group, Prevention Program Research Group. / Impact of lifestyle intervention and metformin on health-related quality of life : the diabetes prevention program randomized trial. In: Journal of General Internal Medicine. 2012 ; Vol. 27, No. 12. pp. 1594-1601.
@article{c94f6a10a5b349128552e6d049f43382,
title = "Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.",
abstract = "Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL). To assess changes in HRQoL after interventions aimed at diabetes risk reduction. A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean age 51 years, mean BMI 34 Kg/m(2); 68 {\%} women, and 45 {\%} members of minority groups. Intensive lifestyle (ILS) program with the goals of at least 7 {\%} weight loss and 150 min of physical activity per week, metformin (MET) 850 mg twice daily, or placebo (PLB). HRQoL using the 36-Item Short-Form (SF-36) health survey to evaluate health utility index (SF-6D), physical component summaries (PCS) and mental component summaries (MCS). A minimally important difference (MID) was met when the mean of HRQoL scores between groups differed by at least 3 {\%}. After a mean follow-up of 3.2 years, there were significant improvements in the SF-6D (+0.008, p=0.04) and PCS (+1.57, p<0.0001) scores in ILS but not in MET participants (+0.002 and +0.15, respectively, p=0.6) compared to the PLB group. ILS participants showed improvements in general health (+3.2, p<0.001), physical function (+3.6, p<0.001), bodily pain (+1.9, p=0.01), and vitality (+2.1, p=0.01) domain scores. Treatment effects remained significant after adjusting sequentially for baseline demographic factors, and for medical and psychological comorbidities. Increased physical activity and weight reduction mediated these ILS treatment effects. Participants who experienced weight gain had significant worsening on the same HRQoL specific domains when compared to those that had treatment-related (ILS or MET) weight loss. No benefits with ILS or MET were observed in the MCS score. Overweight/obese adults at high risk for diabetes show small improvement in most physical HRQoL and vitality scores through the weight loss and increased physical activity achieved with an ILS intervention.",
author = "Hermes Florez and Qing Pan and Ackermann, {Ronald T.} and Marrero, {David G.} and Elizabeth Barrett-Connor and Linda Delahanty and Andrea Kriska and Saudek, {Christopher D.} and Goldberg, {Ronald B.} and Rubin, {Richard R.} and {Diabetes Prevention Program Research Group}, {Prevention Program Research Group}",
year = "2012",
language = "English (US)",
volume = "27",
pages = "1594--1601",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Impact of lifestyle intervention and metformin on health-related quality of life

T2 - the diabetes prevention program randomized trial.

AU - Florez, Hermes

AU - Pan, Qing

AU - Ackermann, Ronald T.

AU - Marrero, David G.

AU - Barrett-Connor, Elizabeth

AU - Delahanty, Linda

AU - Kriska, Andrea

AU - Saudek, Christopher D.

AU - Goldberg, Ronald B.

AU - Rubin, Richard R.

AU - Diabetes Prevention Program Research Group, Prevention Program Research Group

PY - 2012

Y1 - 2012

N2 - Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL). To assess changes in HRQoL after interventions aimed at diabetes risk reduction. A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean age 51 years, mean BMI 34 Kg/m(2); 68 % women, and 45 % members of minority groups. Intensive lifestyle (ILS) program with the goals of at least 7 % weight loss and 150 min of physical activity per week, metformin (MET) 850 mg twice daily, or placebo (PLB). HRQoL using the 36-Item Short-Form (SF-36) health survey to evaluate health utility index (SF-6D), physical component summaries (PCS) and mental component summaries (MCS). A minimally important difference (MID) was met when the mean of HRQoL scores between groups differed by at least 3 %. After a mean follow-up of 3.2 years, there were significant improvements in the SF-6D (+0.008, p=0.04) and PCS (+1.57, p<0.0001) scores in ILS but not in MET participants (+0.002 and +0.15, respectively, p=0.6) compared to the PLB group. ILS participants showed improvements in general health (+3.2, p<0.001), physical function (+3.6, p<0.001), bodily pain (+1.9, p=0.01), and vitality (+2.1, p=0.01) domain scores. Treatment effects remained significant after adjusting sequentially for baseline demographic factors, and for medical and psychological comorbidities. Increased physical activity and weight reduction mediated these ILS treatment effects. Participants who experienced weight gain had significant worsening on the same HRQoL specific domains when compared to those that had treatment-related (ILS or MET) weight loss. No benefits with ILS or MET were observed in the MCS score. Overweight/obese adults at high risk for diabetes show small improvement in most physical HRQoL and vitality scores through the weight loss and increased physical activity achieved with an ILS intervention.

AB - Adults at high risk for diabetes may have reduced health-related quality of life (HRQoL). To assess changes in HRQoL after interventions aimed at diabetes risk reduction. A randomized clinical trial, the Diabetes Prevention Program, was conducted in 27 centers in the United States, in 3,234 non-diabetic persons with elevated fasting and post-load plasma glucose, mean age 51 years, mean BMI 34 Kg/m(2); 68 % women, and 45 % members of minority groups. Intensive lifestyle (ILS) program with the goals of at least 7 % weight loss and 150 min of physical activity per week, metformin (MET) 850 mg twice daily, or placebo (PLB). HRQoL using the 36-Item Short-Form (SF-36) health survey to evaluate health utility index (SF-6D), physical component summaries (PCS) and mental component summaries (MCS). A minimally important difference (MID) was met when the mean of HRQoL scores between groups differed by at least 3 %. After a mean follow-up of 3.2 years, there were significant improvements in the SF-6D (+0.008, p=0.04) and PCS (+1.57, p<0.0001) scores in ILS but not in MET participants (+0.002 and +0.15, respectively, p=0.6) compared to the PLB group. ILS participants showed improvements in general health (+3.2, p<0.001), physical function (+3.6, p<0.001), bodily pain (+1.9, p=0.01), and vitality (+2.1, p=0.01) domain scores. Treatment effects remained significant after adjusting sequentially for baseline demographic factors, and for medical and psychological comorbidities. Increased physical activity and weight reduction mediated these ILS treatment effects. Participants who experienced weight gain had significant worsening on the same HRQoL specific domains when compared to those that had treatment-related (ILS or MET) weight loss. No benefits with ILS or MET were observed in the MCS score. Overweight/obese adults at high risk for diabetes show small improvement in most physical HRQoL and vitality scores through the weight loss and increased physical activity achieved with an ILS intervention.

UR - http://www.scopus.com/inward/record.url?scp=85028123837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028123837&partnerID=8YFLogxK

M3 - Article

C2 - 22692637

AN - SCOPUS:85028123837

VL - 27

SP - 1594

EP - 1601

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 12

ER -